These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Rejection and graft outcomes in kidney transplant recipients with and without angiotensin II receptor type 1 antibodies. Aljishi M; Isbel NM; Jegatheesan D; Johnson DW; Cho Y; Campbell SB; Hawley CM; Thornton A; Gillis D; Johnstone K Transpl Immunol; 2023 Feb; 76():101756. PubMed ID: 36460263 [TBL] [Abstract][Full Text] [Related]
27. Acute kidney transplant rejection mediated by angiotensin II type 1 receptor antibodies in a pediatric hyperimmune patient. Guzzo I; Morolli F; Camassei FD; Piazza A; Poggi E; Dello Strologo L Pediatr Nephrol; 2017 Jan; 32(1):185-188. PubMed ID: 27752765 [TBL] [Abstract][Full Text] [Related]
28. Effect of anti-angiotensin II type 1 receptor antibodies on the outcomes of kidney transplantation: a systematic review and meta-analysis. Kang ZY; Liu C; Liu W; Li DH Nephrol Dial Transplant; 2022 May; 37(6):1171-1180. PubMed ID: 34865146 [TBL] [Abstract][Full Text] [Related]
29. Non-HLA Antibodies in Hand Transplant Recipients Are Connected to Multiple Acute Rejection Episodes and Endothelial Activation. Sikorska D; Kamińska D; Catar R; Banasik M; Heidecke H; Schulze-Forster K; Korybalska K; Rutkowski R; Łuczak J; Jabłecki J; Oko A; Daroszewski P; Kusztal M; Samborski W J Clin Med; 2022 Feb; 11(3):. PubMed ID: 35160284 [TBL] [Abstract][Full Text] [Related]
30. The early impact of preformed angiotensin II type 1 receptor antibodies on graft function in a low immunological risk cohort of kidney transplant recipients. Sorohan BM; Ismail G; Berechet A; Obrișcă B; Constantinescu I; Mărunțelu I; Tacu D; Baston C; Sinescu I Transpl Immunol; 2021 Jun; 66():101389. PubMed ID: 33838295 [TBL] [Abstract][Full Text] [Related]
31. The impact of non-HLA antibodies directed against endothelin-1 type A receptors (ETAR) on early renal transplant outcomes. Banasik M; Boratyńska M; Kościelska-Kasprzak K; Krajewska M; Mazanowska O; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Nowakowska B; Hałoń A; Dawiskiba T; Chudoba P; Klinger M Transpl Immunol; 2014 Jan; 30(1):24-9. PubMed ID: 24184747 [TBL] [Abstract][Full Text] [Related]
32. Pre-transplant Screening for Non-HLA Antibodies: Who should be Tested? Philogene MC; Zhou S; Lonze BE; Bagnasco S; Alasfar S; Montgomery RA; Kraus E; Jackson AM; Leffell MS; Zachary AA Hum Immunol; 2018 Apr; 79(4):195-202. PubMed ID: 29428484 [TBL] [Abstract][Full Text] [Related]
33. Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies. Philogene MC; Bagnasco S; Kraus ES; Montgomery RA; Dragun D; Leffell MS; Zachary AA; Jackson AM Transplantation; 2017 Mar; 101(3):608-615. PubMed ID: 27222934 [TBL] [Abstract][Full Text] [Related]
34. The role of endothelin II type A receptor (ETAR) in transplant injury. Nowańska K; Wiśnicki K; Kuriata-Kordek M; Krajewska M; Banasik M Transpl Immunol; 2022 Feb; 70():101505. PubMed ID: 34793957 [TBL] [Abstract][Full Text] [Related]
35. Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Günther J; Kill A; Becker MO; Heidecke H; Rademacher J; Siegert E; Radić M; Burmester GR; Dragun D; Riemekasten G Arthritis Res Ther; 2014 Mar; 16(2):R65. PubMed ID: 24612997 [TBL] [Abstract][Full Text] [Related]
36. Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies. Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A Nephrology (Carlton); 2019 Mar; 24(3):347-356. PubMed ID: 29451342 [TBL] [Abstract][Full Text] [Related]
37. Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal. Ohe H; Uchida Y; Yoshizawa A; Hirao H; Taniguchi M; Maruya E; Yurugi K; Hishida R; Maekawa T; Uemoto S; Terasaki PI Transplantation; 2014 Nov; 98(10):1105-11. PubMed ID: 24914568 [TBL] [Abstract][Full Text] [Related]
38. Prevalence of AT1R antibody (AT1R-Ab) among Malaysian multi-ethnic population. Jalalonmuhali M; Caroll R; Deayton S; Emery T; Humphreys I; Lim SJ; Lim SK; Coates T Hum Immunol; 2020 Dec; 81(12):679-684. PubMed ID: 32736900 [TBL] [Abstract][Full Text] [Related]
39. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes. Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Zmonarski S; Protasiewicz M; Nowakowska B; Hałoń A; Chudoba P; Klinger M Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812 [TBL] [Abstract][Full Text] [Related]
40. Non-HLA antibodies targeting angiotensin II Type 1 receptor and endothelin-1 Type A receptors induce endothelial injury via β2-arrestin link to mTOR pathway. Catar RA; Wischnewski O; Chen L; Heidecke H; Rutz C; Schülein R; Dragun D; Philippe A; Kusch A Kidney Int; 2022 Mar; 101(3):498-509. PubMed ID: 34757123 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]